.png){kind=icon}
返回
Atherosclerosis
.png){kind=icon}
PRE
AI
DOI：10.1038/s41572-019-0106-z.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Atherosclerosis, the formation of fibrofatty lesions in the artery wall, causes much morbidity and mortality worldwide, including most myocardial infarctions and many strokes, as well as disabling peripheral artery disease. Development of atherosclerotic lesions probably requires low-density lipoprotein, a particle that carries cholesterol through the blood. Other risk factors for atherosclerosis and its thrombotic complications include hypertension, cigarette smoking and diabetes mellitus. Increasing evidence also points to a role of the immune system, as emerging risk factors include inflammation and clonal haematopoiesis. Studies of the cell and molecular biology of atherogenesis have provided considerable insight into the mechanisms that link all these risk factors to atheroma development and the clinical manifestations of this disease. An array of diagnostic techniques, both invasive (such as selective coronary arteriography) and noninvasive (such as blood biomarkers, stress testing, CT and nuclear scanning), permit assessment of cardiovascular disease risk and targeting of therapies. An expanding armamentarium of therapies that can modify risk factors and confer clinical benefit is available; however, we face considerable challenge in providing equitable access to these treatments and in maximizing adherence. Yet, the clinical application of the fruits of research has advanced preventive strategies, enhanced clinical outcomes in affected individuals, and improved their quality of life. Rapidly accelerating knowledge and continued research promise to provide further progress in combating this common chronic disease.
Keyword:
QUALITY-OF-LIFE
CORONARY-ARTERY-DISEASE
CARDIOVASCULAR RISK-FACTORS
DENSITY-LIPOPROTEIN CHOLESTEROL
LEUKOCYTE ADHESION MOLECULE
HUMAN VASCULAR ENDOTHELIUM
SMOOTH-MUSCLE-CELLS
PRIMARY PREVENTION
CLONAL HEMATOPOIESIS
STATIN THERAPY
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
N
IF:
60.6
论文数:
652
被引数:
3.8W
机构
引用论文
分享收藏2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines2013 ACC/AHA治疗血液胆固醇以降低成人动脉粥样硬化性心血管风险指南美国心脏病学会/美国心脏协会实践指南工作组的报告.png)
CIRCULATION
OAAI
CIRCULATIONIF38.6
OAAI分享收藏Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials强化降低LDL胆固醇的有效性和安全性: 来自26项随机试验170 000名参与者的荟萃分析LANCETOAAI
LANCETIF88.5
OAAI分享收藏
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIEREvolocumab在冠状动脉疾病严重程度和程度方面的临床获益: 傅立叶分析CIRCULATIONOAAI
CIRCULATIONIF38.6
OAAI分享收藏
查看更多内容